BACKGROUND: ). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks. METHODS: In this phase 2 portion of a phase 1-2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo. The primary end point was the number of angioedema attacks per month (the monthly attack rate) from week 1 through week 16. Secondary end points included safety, pharmacokinetics, and pharmacodynamics (i.e., the change from baseline in total plasma kallikrein protein level); exploratory end points included patient-reported outcomes. RESULTS: Of the 27 patients who underwent randomization, 10 received 25 mg of NTLA-2002, 11 received 50 mg, and 6 received placebo. From week 1 through week 16, the estimated mean monthly attack rate was 0.70 (95% confidence interval [CI], 0.25 to 1.98) with 25 mg of NTLA-2002, 0.65 (95% CI, 0.24 to 1.76) with 50 mg, and 2.82 (95% CI, 0.80 to 9.89) with placebo; the difference in the estimated mean attack rate with NTLA-2002 as compared with placebo was -75% with 25 mg and -77% with 50 mg. Among patients who received NTLA-2002, 4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free with no additional treatment during the period from week 1 through week 16. The most common adverse events among patients who received NTLA-2002 were headache, fatigue, and nasopharyngitis. The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was -55% with 25 mg and -86% with 50 mg; levels remained unchanged with placebo. CONCLUSIONS: NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema. These results support continued investigation in a larger phase 3 trial. (Funded by Intellia Therapeutics; ClinicalTrials.gov number, NCT05120830; EudraCT number, 2021-001693-33.).
NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.
small exploratory randomized comparison with a 16-week primary window and clinical effect intervals including no benefit
The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was -55% with 25 mg and -86% with 50 mg; levels remained unchanged with placebo.
direct pharmacodynamic measurements show consistent dose-dependent lowering relative to unchanged placebo levels
Among patients who received NTLA-2002, 4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free with no additional treatment during the period from week 1 through week 16.
directly reported descriptive counts in small treatment groups over a short primary observation period
12 of 15 patients (80%) who received 50 mg of NTLA-2002 have remained attack-free for periods ranging from 12 weeks (phase 2) to approximately 19 months (phase 1)
pooled small cohorts with heterogeneous follow-up and an uncontrolled phase 1 extension
No new safety concerns arose, and no serious adverse events occurred in patients who received NTLA-2002.
observed event reporting in a small treated population with insufficient exposure to exclude rare or delayed harms
Derived from the full evaluation — not a separate score.
Strengths
The placebo-controlled phase 2 comparison extends prior dose-escalation findings with clinical attack-rate estimates and attack-free proportions in patients.
↳ Introduction — prior phase 1 study; Methods — Trial Design; Results — Efficacy
All randomized patients enter the efficacy analysis, the primary model adjusts for baseline attack rate, and adverse events are graded and reported with denominators.
↳ Methods — Clinical Assessment and Statistical Analysis; Table 3
The single-infusion strategy addresses the burden of repeated lifelong prophylaxis, and the conclusion identifies a larger phase 3 trial as the next step.
↳ Introduction — prophylaxis burden; Discussion — final paragraph
Limitations
The trial randomized 27 patients, including six placebo recipients, without a formal power calculation. Primary percentage-difference intervals span -95 to 27 and -95 to 15, including no benefit.
↳ Methods — Statistical Analysis; Table 2
The abstract states that NTLA-2002 reduced attacks, while the primary placebo comparisons remain inconclusive. The functional-cure framing is prospective rather than demonstrated.
↳ Abstract — Conclusions; Table 2; Discussion — final paragraph
The 16-week controlled window and limited treated population cannot resolve rare or delayed harms. Discussion gives limited attention to editing-specific long-term risks.
↳ Methods — primary observation period; Table 3; Discussion — safety and limitations
The randomized, double-blind design and baseline-adjusted analysis make this a meaningful extension of the prior phase 1 study. Dose-dependent kallikrein lowering provides direct pharmacodynamic evidence, while the clinical point estimates remain imprecise because the placebo-controlled sample is small. The clarity score reflects the gap between unqualified attack-reduction wording and primary comparative intervals that include no benefit. The phase 3 recommendation and discussion of longer follow-up temper the contextual concern, but do not establish a functional cure. An unexplained enrollment change from a plan of up to 25 to 27 randomized patients is retained as a reporting note without evidence that it changes the reported results.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.6
Confidence highThe randomized placebo comparison adds clinical evidence beyond the prior dose-escalation study for a single-dose editing strategy. The small exploratory trial meaningfully extends prior work without settling efficacy.
Blinding, analysis of all randomized patients, baseline-adjusted negative binomial modeling, and systematic harms collection support competent early-phase execution. Precision and assessability are constrained by the sample size, short primary window, and undocumented concealment and incomplete-observation handling.
The statistical caveats and trial structure are clearly reported. Unqualified headline attack-reduction wording exceeds the certainty of the placebo comparison, producing a 0.4-point reduction from the clarity merit assessment.
The paper distinguishes its mechanism and randomized contribution from established prophylaxis and prior phase 1 work. Phase 3 framing and durability discussion temper the conclusions, but editing-specific long-term risks and effect-size benchmarking receive limited treatment.
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Caveats4 of 4 checks
One reported value does not reconcile, but the key claims do not rest on it.
Ethics approval, informed consent, trial registration, funding, and sponsor involvement are disclosed. Referenced oversight and data-sharing materials were not independently verified.
Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared
21 of 21 checkable references verified
24 references in manuscript 3 have no canonical index record — counted, but not index-checkable 2 references confirmed by manual review
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The therapy has been evaluated in patients across multiple centers with clinical attack outcomes and rescue-medication use. The small phase 2 dataset and short controlled observation period leave substantial work before clinical deployment.
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
Well-supportedRiedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine
Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate
SupportedAygören-Pürsün, Zanichelli, Cohn, et al. · 2023 · Clinical medicine
Time to use of conventional treatment within 12 h of study drug administration was significantly longer with sebetralstat versus placebo
Supported